Venture capital deals

April 29, 2013, 5:59 PM UTC

Opsona Therapeutics Ltd., a Dublin-based innate immune drug development company, has raised €33 million in Series C funding. BB Biotech Ventures and return backer Novartis Venture Fund co-led the round. Other new investors included Sunstone Capital, Baxter Ventures, Amgen Ventures and EMBL Ventures, while other returnees included Fountain Healthcare Partners, Roche Venture Fund and Seroba Kernel Life Sciences.

RainDance Technologies Inc., a Lexington, Mass.-based developer of microdroplet-based solutions for single molecule and single cell analysis, has raised $20 million in Series E funding. Myriad Genetics Inc. (Nasdaq: MYGN) was joined by return backers Mohr Davidow Ventures, Quaker BioVentures, Alloy Ventures, Acadia Woods Partners and Sectoral Asset

Sign up for Dan’s daily email newsletter on deals and deal-makers:


Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.